Treatment of neurological autoimmune diseases with immunoglobulins: First insights from the prospective signs registry

Journal of Clinical Immunology

Volumn 33, Issue SUPPL.1, 2013, Pages

  Stangel, Martin ^a   Baumann, Ulrich ^a   Borte, Michael ^b   Fasshauer, Maria ^b   Hensel, Manfred ^c   Huscher, Dörte ^d   Kirch, Wilhelm ^e   Pittrow, David ^e   Reiser, Marcel ^f   Gold, Ralf ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Klinikum St Georg   (Germany)

^c Mannheimer Onkologie Praxis   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f PIOH Praxis Internistische Onkologie   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

Author keywords

immunodeficiency; management; neuroimmunology; Observational; outcomes research; patient related outcomes; pharmacoeconomics; quality of life; routine care; therapy

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DISEASE DURATION; DISEASE REGISTRY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; IMMUNOTHERAPY; INTERNET; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOSITIS; NEUROLOGIC DISEASE; NEUROLOGICAL AUTOIMMUNE DISEASE; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; SHORT FORM 36;

ADULT; AGED; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OFF-LABEL USE; QUALITY OF LIFE; REGISTRIES; TREATMENT OUTCOME;

EID: 84872610016     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9789-6     Document Type: Review

References (23)

1. Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sorensen P, Udd B. FNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893-908.
2. Stangel M, Gold R. Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010 [Article in German]. Nervenarzt. 2011;82:415-30.
3. Stangel M. New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Ther Adv Neurol Disord. 2008;1:52-61.
4. Gold R, Stangel M, Dalakas MC. Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3:36-44. (Pubitemid 46056032)
5. Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7:337-42.
6. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009;16:631-8.
7. Kirch W, Stangel M, Pittrow D, Baumann U, Fasshauer M, Huscher D, Hensel M, Reiser M, Gold R, Borte M. Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry. J Public Health. 2012;20:289-96.
8. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
9. Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124-30. (Pubitemid 40905009)
10. World Health Organisation (WHO). WHO-5 interpretation. Internet: http://www.cure4you.dk/354/index.php?m=2&a=e2&ei=4151. Accessed on 12 November 2011.
11. Fahrenberg J, Myrtek M, Schumacher J, Brähler E. Fragebogen zur Lebenszufriedenheit (FLZ). Handanweisung. Göttingen: Hogrefe Verlag für Psychologie; 2000.
12. Anonymous. SF-36. US population norm values (1998). Internet: http://www.sf-36.org/research/sf98norms.pdf. Accessed on 11 November 2011.
13. Schwarz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Mult Scler. 2008;14:1113-9.
14. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136-44.
15. Hughes RA. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Expert Rev Neurother. 2009;9:789-95.
16. Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010;81:1194-9.
17. Merkies IS, Bril V, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung HP, Hughes RA, Latov N, van Doorn PA. Health-related quality-of-life improvements in CIDP with immune globulin IV 10 %: the ICE Study. Neurology. 2009;72:1337-44.
18. van der Pol WL, Cats EA, van den Berg LH. Intravenous immunoglobulin treatment in multifocal motor neuropathy. J Clin Immunol. 2010;30 Suppl 1:S79-83.
19. Cats EA, van der Pol WL, Piepers S, Notermans NC, van den Berg-Vos RM, van den Berg LH. New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability. J Neurol. 2008;255:1598-9.
20. European Medicines Agency (EMA). Kiovig. Human normal immunoglobulin (IVIg). Summary of opinion (Document EMA/CHMP/495548/2011). Internet: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/ 000628/WC500107997.pdf. Accessed on 31 October 2011.
21. Morfeld M, Bullinger M, Nantke J, Brahler E. The version 2.0 of the SF-36 health survey: results of a population-representative study. Soz Präventivmed. 2005;50:292-300. (Pubitemid 41684561)
22. Bellach B, Ellert U, Radoschewski M. Der SF-36 im Bundesgesundheitssurvey - Erste Ergebnisse und neue Fragen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2000;43:210-6.
23. Kirch W, Gold R, Hensel M, Fasshauer M, Pittrow D, Huscher D, Reiser M, Stangel M, Baumann U, Borte M. Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods. Med Klin (Munich). 2010;105:647-51.